Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma

Fig. 2

IRF6 was epigenetically repressed in UC cells. a mRNA expression of IRF6 in UC cells treated with TSA, 5aza, alone or in combination were examined by qRT-PCR. Each error bar represents mean ± SD from triplicates. b Methylation analysis of IRF6 promoter in various UC cells using (b) COBRA and (c) bisulphite pyrosequencing. In the COBRA assays, bisulfite-modified DNA was amplified and digested using AciI. U, undigested control; C, digested using AciI; M, DNA ladder marker; IVD, in vitro methylated DNA. Upper panel in (b) and (c) indicates the genomic structure of IRF6 promoter with the corresponding location of CpG sites. Blue line and red line indicate the region for COBRA and bisulphite pyrosequencing (6 CpG sites), respectively. Methylation analysis of IRF6 promoter by bisulphite pyrosequencing in UMUC3 treated with (d) epigenetic drugs and (e) CPH were also indicated. Original gel image of (b) can be found in Additional file 3

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us